Joseph Laukaitis, MD
Rheumatology · Washington, DCNPI 1083726210
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 481 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,284 and has fallen 79.8% since, to $461 in 2024.
Across 481 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Lilly USA, LLC$1K
- Johnson & Johnson$1K
- Novartis$1K
- AbbVie$567
- AstraZeneca$537
- plus $3K from 36 others
What the payments were for
- Food & beverage$9,569100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,571 in reported general payments places this provider in the 65th percentile of 41 rheumatology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 16 | $272,340 |
| Enbrel SureclickEtanercept | 16 | $172,522 |
| Cevimeline Hcl | 19 | $3,995 |
| MethotrexateMethotrexate Sodium | 50 | $2,720 |
| Hydroxychloroquine Sulfate | 24 | $1,339 |
| Alendronate Sodium | 45 | $818 |
| Allopurinol | 42 | $585 |
| Pregabalin | 12 | $575 |
| Meloxicam | 37 | $421 |
| Duloxetine Hcl | 20 | $312 |
| Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen | 15 | $271 |
| Prednisone | 19 | $227 |
| Diclofenac Sodium | 18 | $180 |
| Folic Acid | 14 | $153 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Washington
- Stephen MitchellWashington$1.6M
- Andrea Leonard-SegalWashington$633K
- Gail KerrWashington$244K
- Virginia SteenWashington$168K
- Sharon DowellWashington$73K
- Christopher CollinsWashington$69K
- Saira BilalWashington$62K
- Megan LockwoodWashington$23K
- Mercedes QuinonesWashington$23K
- Tayseer HarounWashington$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.